Literature DB >> 1979366

Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon.

C B Bunker1, G Terenghi, D R Springall, J M Polak, P M Dowd.   

Abstract

Skin biopsy samples from the fingers of nine patients with primary Raynaud's phenomenon, nine with the disorder associated with systemic sclerosis, and eleven healthy controls were examined by immunocytochemistry. There were no differences between the groups in the distribution of PGP 9.5 (a pan-neuronal marker) immunoreactivity, but there was a significant reduction in the number of calcitonin gene-related peptide (CGRP) immunoreactive neurons in the skin of patients with primary Raynaud's phenomenon and those with systemic sclerosis. These findings implicate dysfunction of the CGRP neurovascular axis in the pathophysiology of Raynaud's phenomenon.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979366     DOI: 10.1016/0140-6736(90)93307-b

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

Review 1.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

2.  Primary and secondary Raynaud's phenomenon: does small neuropathy remain the same?

Authors:  Gianluigi Bajocchi; Rossana Terlizzi; Ilaria Chiarolanza; Pietro Cortelli
Journal:  Rheumatol Int       Date:  2011-07       Impact factor: 2.631

Review 3.  [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

4.  Calcitonin gene related peptide.

Authors:  D J O'Halloran; S R Bloom
Journal:  BMJ       Date:  1991-03-30

Review 5.  New lines in therapy of Raynaud's phenomenon.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

6.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

7.  Finger skin temperature in patients affected by Raynaud's phenomenon with or without anticentromere antibody positivity.

Authors:  P Caramaschi; D Biasi; A Carletto; T Manzo; M Randon; S Zeminian; L M Bambara
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 8.  Endothelins. A potential target for pharmacological intervention in diseases of the elderly.

Authors:  H Lévesque; N Moore; N Cailleux; V Richard; C Thuillez; H Courtois
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

Review 9.  Recent achievements in the management of Raynaud's phenomenon.

Authors:  Magnus Baumhäkel; Michael Böhm
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

10.  Raynaud's phenomenon.

Authors:  Ashraful Haque; Michael Hughes
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.